Encephalitis Market Report and Forecast 2025-2034
Description
The encephalitis market size in the 7 major markets was valued at USD 20.85 Billion in 2024, driven by the increasing incidence and awareness about encephalitis among people. The market size is anticipated to grow at a CAGR of 5.04% during the forecast period of 2025-2034 to achieve a value of USD 34.09 Billion by 2034.
Encephalitis: Introduction
Encephalitis refers to the inflammation of the brain, stemming from various sources such as viral infections, autoimmune responses, bacterial infections, insect bites, and other triggers. The inflammation resulting from an infection within the brain is classified as infectious encephalitis. Conversely, when the immune system targets and inflames the brain, it is termed autoimmune encephalitis. At times, the cause remains unidentified. In certain instances, encephalitis can pose life-threatening risks. Swift diagnosis and treatment hold crucial significance due to the unpredictable nature of how encephalitis impacts everyone.
Encephalitis Market Analysis
The market growth is driven by significant developments in both pharmaceutical acquisitions and groundbreaking research. For example, Pfizer’s monumental acquisition of Seagen, aimed at diversifying its revenue streams amidst the anticipated decline in COVID-19 product sales and patent expirations, stands as a pivotal move. This acquisition not only provides Pfizer access to Seagen’s lucrative portfolio but also bolsters its already impressive range of approved oncological therapies, potentially influencing the treatment landscape for conditions like autoimmune brain inflammation. This acquisition may further develop a suitable and cutting-edge treatment therapy for better patient outcomes as Seagen is already familiar with the field, bolstering the encephalitis market growth.
Moreover, recent developments in research are further transforming the treatment landscape for autoimmune brain conditions such as encephalitis. For example, the innovative development of specialized CAAR-T cells designed to target and eliminate cells producing harmful antibodies, showcases promising strides in precision medicine. This innovative approach, exhibiting efficacy in preclinical models, signifies a potential development in treating autoimmune brain inflammation, a critical aspect of encephalitis. Such innovative developments are further expected to increase the encephalitis market demand.
Additionally, the emergence of a potential therapeutic agent for autoimmune encephalitis resulting from translational research is further expected to drive the market demand as it will result in more research for the treatment of the condition. This discovery brings hope for a targeted treatment option that could significantly impact the market.
Encephalitis Market Segmentations
“Encephalitis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The market is poised to witness substantial growth during the forecast period owing to various factors. The increasing prevalence of encephalitis worldwide, especially in the 7 major markets, coupled with determined efforts to enhance diagnosis and treatment options, is anticipated to be a major factor driving the market growth in the forecast period. The high mortality and morbidity rates resulting from the encephalitis virus signifies the urgent need for effective solutions, expected to increase the demand for effective treatment, therefore propelling the encephalitis market growth further. Initiatives supported by the government such as government-led vaccination programs are expected to play a pivotal role in stimulating market demand, exhibiting the will to approach disease prevention.
Moreover, the collaborative efforts of public and private organizations in awareness campaigns and the increased investment by the government are further expected to amplify the market reach. Factors such as a rise in disposable income, a burgeoning geriatric population, and evolving lifestyles are expected to further fuel market growth by increasing the demand for encephalitis treatments. Significantly, the surge in research and development activities, alongside substantial investments from both governmental and private sectors, are paving the road for further market growth.
Encephalitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Encephalitis: Introduction
Encephalitis refers to the inflammation of the brain, stemming from various sources such as viral infections, autoimmune responses, bacterial infections, insect bites, and other triggers. The inflammation resulting from an infection within the brain is classified as infectious encephalitis. Conversely, when the immune system targets and inflames the brain, it is termed autoimmune encephalitis. At times, the cause remains unidentified. In certain instances, encephalitis can pose life-threatening risks. Swift diagnosis and treatment hold crucial significance due to the unpredictable nature of how encephalitis impacts everyone.
Encephalitis Market Analysis
The market growth is driven by significant developments in both pharmaceutical acquisitions and groundbreaking research. For example, Pfizer’s monumental acquisition of Seagen, aimed at diversifying its revenue streams amidst the anticipated decline in COVID-19 product sales and patent expirations, stands as a pivotal move. This acquisition not only provides Pfizer access to Seagen’s lucrative portfolio but also bolsters its already impressive range of approved oncological therapies, potentially influencing the treatment landscape for conditions like autoimmune brain inflammation. This acquisition may further develop a suitable and cutting-edge treatment therapy for better patient outcomes as Seagen is already familiar with the field, bolstering the encephalitis market growth.
Moreover, recent developments in research are further transforming the treatment landscape for autoimmune brain conditions such as encephalitis. For example, the innovative development of specialized CAAR-T cells designed to target and eliminate cells producing harmful antibodies, showcases promising strides in precision medicine. This innovative approach, exhibiting efficacy in preclinical models, signifies a potential development in treating autoimmune brain inflammation, a critical aspect of encephalitis. Such innovative developments are further expected to increase the encephalitis market demand.
Additionally, the emergence of a potential therapeutic agent for autoimmune encephalitis resulting from translational research is further expected to drive the market demand as it will result in more research for the treatment of the condition. This discovery brings hope for a targeted treatment option that could significantly impact the market.
Encephalitis Market Segmentations
“Encephalitis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Primary Encephalitis
- Secondary Encephalitis
- Antiviral Agents
- Steroid Injection
- Antibiotics
- Immunoglobulin Therapy
- Plasmapheresis
- Others
- Imaging Tests
- Blood Tests
- Biopsy
- Others
- Injection
- Tablets
- Others
- Oral
- Parenteral
- Others
- Hospital Pharmacy
- Retail Pharmacy
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
The market is poised to witness substantial growth during the forecast period owing to various factors. The increasing prevalence of encephalitis worldwide, especially in the 7 major markets, coupled with determined efforts to enhance diagnosis and treatment options, is anticipated to be a major factor driving the market growth in the forecast period. The high mortality and morbidity rates resulting from the encephalitis virus signifies the urgent need for effective solutions, expected to increase the demand for effective treatment, therefore propelling the encephalitis market growth further. Initiatives supported by the government such as government-led vaccination programs are expected to play a pivotal role in stimulating market demand, exhibiting the will to approach disease prevention.
Moreover, the collaborative efforts of public and private organizations in awareness campaigns and the increased investment by the government are further expected to amplify the market reach. Factors such as a rise in disposable income, a burgeoning geriatric population, and evolving lifestyles are expected to further fuel market growth by increasing the demand for encephalitis treatments. Significantly, the surge in research and development activities, alongside substantial investments from both governmental and private sectors, are paving the road for further market growth.
Encephalitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Allergan
- Merck & Co.
- Pfizer Inc.
- GlaxoSmithKline plc
- Melinta Therapeutics LLC
- Basilea Pharmaceutica Ltd
- Abbott
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Cumberland Pharmaceuticals
- Fresenius Kabi AG
- Lupin
- AbbVie Inc.
- Endo International plc
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Encephalitis Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Encephalitis Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Encephalitis Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Encephalitis Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Encephalitis Epidemiology Forecast (2018-2034)
- 5.3.2 France Encephalitis Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Encephalitis Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Encephalitis Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Encephalitis Epidemiology Forecast (2018-2034)
- 5.4 Japan Encephalitis Epidemiology Forecast (2018-2034)
- 6 Encephalitis Market Overview – 7MM
- 6.1 Encephalitis Market Historical Value (2018-2024)
- 6.2 Encephalitis Market Forecast Value (2025-2034))
- 7 Encephalitis Market Landscape-7MM
- 7.1 Encephalitis Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Encephalitis Product Landscape
- 7.2.1 Analysis by Diseases Type
- 7.2.2 Analysis by Treatments
- 7.2.3 Analysis by Route of Administration
- 8 Encephalitis Treatment Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Encephalitis Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Encephalitis Market Segmentation -7MM
- 11.1 Encephalitis Market by Type
- 11.1.1 Market Overview
- 11.1.2 Primary Encephalitis
- 11.1.3 Secondary Encephalitis
- 11.2 Encephalitis Market by Treatment
- 11.2.1 Market Overview
- 11.2.2 Antiviral Agents
- 11.2.3 Steroid Injection
- 11.2.4 Antibiotics
- 11.2.5 Immunoglobulin Therapy
- 11.2.6 Plasmapheresis
- 11.2.7 Others
- 11.3 Encephalitis Market by Diagnosis
- 11.3.1 Market Overview
- 11.3.2 Imaging Tests
- 11.3.3 Blood Tests
- 11.3.4 Biopsy
- 11.3.5 Others
- 11.4 Encephalitis Market by Dosage
- 11.4.1 Market Overview
- 11.4.2 Injection
- 11.4.3 Tablets
- 11.4.4 Others
- 11.5 Encephalitis Market by Route of Administration
- 11.5.1 Market Overview
- 11.5.2 Oral
- 11.5.3 Parenteral
- 11.5.4 Others
- 11.6 Encephalitis Market by Distribution Channel
- 11.6.1 Market Overview
- 11.6.2 Hospital Pharmacy
- 11.6.3 Retail Pharmacy
- 11.7 Encephalitis Market by Region
- 11.7.1 Market Overview
- 11.7.2 United States
- 11.7.3 EU-4 and the United Kingdom
- 11.7.3.1 Germany
- 11.7.3.2 France
- 11.7.3.3 Italy
- 11.7.3.4 Spain
- 11.7.3.5 United Kingdom
- 11.7.4 Japan
- 12 United States Encephalitis Market
- 12.1 Encephalitis Market Historical Value (2018-2024)
- 12.2 Encephalitis Market Forecast Value (2025-2034)
- 12.3 Encephalitis Market by Disease Type
- 12.4 Encephalitis Market by Treatment Type
- 13 EU-4 and United Kingdom Encephalitis Market
- 13.1 Encephalitis Market Historical Value (2018-2024)
- 13.2 Encephalitis Market Forecast Value (2025-2034)
- 13.3 Germany Encephalitis Market Overview
- 13.3.1 Encephalitis Market by Disease Type
- 13.3.2 Encephalitis Market by Treatment Type
- 13.4 France Encephalitis Market Overview
- 13.4.1 Encephalitis Market by Disease Type
- 13.4.2 Encephalitis Market by Treatment Type
- 13.5 Italy Encephalitis Market Overview
- 13.5.1 Encephalitis Market by Disease Type
- 13.5.2 Encephalitis Market by Treatment Type
- 13.6 Spain Encephalitis Market Overview
- 13.6.1 Encephalitis Market by Disease Type
- 13.6.2 Encephalitis Market by Treatment Type
- 13.7 United Kingdom Encephalitis Market Overview
- 13.7.1 Encephalitis Market by Disease Type
- 13.7.2 Encephalitis Market by Treatment Type
- 14 Japan Encephalitis Market
- 14.1 Encephalitis Market Historical Value (2018-2024)
- 14.2 Encephalitis Market Forecast Value (2025-2034)
- 14.2.1 Encephalitis Market by Disease Type
- 14.2.2 Encephalitis Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Allergan
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Merck & Co.
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Pfizer Inc.
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 GlaxoSmithKline plc
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Melinta LLC
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Basilea Pharmaceutica Ltd
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Abbott
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 F. Hoffmann-La Roche Ltd.
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 Mylan N.V.
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Teva Pharmaceutical Industries Ltd.
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Cumberland Pharmaceuticals
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Fresenius Kabi AG
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Lupin
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 AbbVie Inc.
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 Endo International plc
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Encephalitis Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
